Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.

CONCLUSION: Based on data from our patient cohort of Japanese women with HER2-positive early-stage breast cancer, the efficacy and safety of systemic therapy with TZM are comparable to data from previously conducted large trials. Progress in anti-HER2 therapy for patients aged ≥70 years who have a poorer prognosis is needed.
PMID: 25666483 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - February 10, 2015 Category: Cancer & Oncology Authors: Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M Tags: Int J Clin Oncol Source Type: research